Gradalis Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014103)
◆英語タイトル:Gradalis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014103
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:23
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals, is a biopharmaceutical company which focuses on the development and commercialization of therapies for the treatment of cancer. Its developmental pipeline comprises of candidates for various cancer indications which include ovarian, breast, melanoma, Ewing’s sarcoma, non-small cell lung, colon, hepatocellular, carcinoid, and sarcomas. Gradalis developed a proprietary immunotherapy platform, Vigil which is utilized in various advanced cancer indications. Vigil is intended to stimulate and enhance the patient’s natural mechanism for recognizing and killing the cancer cells. The company operates a manufacturing facility located in Carrolton, Texas. Gradalis is headquartered in Dallas, Texas, the US.

Gradalis Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gradalis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Gradalis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gradalis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Gradalis Raises US$24 Million In Series B Financing 10
Partnerships 11
Gradalis Enters into Agreement with Genentech 11
Gradalis Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 12
Gradalis Enters Into Co-Development Agreement With Baylor College of Medicine 13
Gradalis Inc – Key Competitors 14
Gradalis Inc – Key Employees 15
Gradalis Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
May 04, 2016: Gradalis Appoints Sunil Joshi Chief Executive Officer 17
Product News 18
10/24/2016: Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board 18
10/17/2016: Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX 19
01/03/2017: Cryoport Supports Gradalis’ Vigil Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers 20
Clinical Trials 21
Aug 29, 2016: Gradalis Announces Dosing of First Patient in Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast Cancer 21
Apr 26, 2016: Gradalis, Announces Initiation of a Phase 2 Study using Gradalis’ Vigil Immunotherapy in Combination with Anti-PD-1 Technology to Treat Patients with Advanced Non-Small Cell Lung Cancer 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Gradalis Inc, Pharmaceuticals & Healthcare, Key Facts 2
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gradalis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gradalis Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Gradalis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gradalis Raises US$24 Million In Series B Financing 10
Gradalis Enters into Agreement with Genentech 11
Gradalis Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 12
Gradalis Enters Into Co-Development Agreement With Baylor College of Medicine 13
Gradalis Inc, Key Competitors 14
Gradalis Inc, Key Employees 15
Gradalis Inc, Other Locations 16

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Gradalis Inc-製薬・医療分野:企業M&A・提携分析(Gradalis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆